{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T16:37:30Z","timestamp":1791218250013,"version":"4.1.0"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2014,8,23]],"date-time":"2014-08-23T00:00:00Z","timestamp":1408752000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["World J Urol"],"published-print":{"date-parts":[[2015,6]]},"DOI":"10.1007\/s00345-014-1383-5","type":"journal-article","created":{"date-parts":[[2014,8,22]],"date-time":"2014-08-22T04:57:38Z","timestamp":1408683458000},"page":"847-852","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":25,"title":["Mixed low- and high-grade non-muscle-invasive bladder cancer: a histological subtype with favorable outcome"],"prefix":"10.1007","volume":"33","author":[{"given":"Tina","family":"Schubert","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew R.","family":"Danzig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Srinath","family":"Kotamarti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rashed A.","family":"Ghandour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danny","family":"Lascano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Byron P.","family":"Dubow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G. Joel","family":"Decastro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitchell C.","family":"Benson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James M.","family":"McKiernan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2014,8,23]]},"reference":[{"issue":"4","key":"1383_CR1","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1016\/j.eururo.2013.06.003","volume":"64","author":"M Babjuk","year":"2013","unstructured":"Babjuk M, Burger M, Zigeuner R et al (2013) EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2013. Eur Urol 64(4):639\u2013653","journal-title":"Eur Urol"},{"issue":"5","key":"1383_CR2","doi-asserted-by":"crossref","first-page":"277","DOI":"10.3322\/caac.20073","volume":"60","author":"A Jemal","year":"2010","unstructured":"Jemal A, Siegel R, Xu J, Ward E (2010) Cancer statistics, 2010. CA Cancer J Clin 60(5):277\u2013300","journal-title":"CA Cancer J Clin"},{"issue":"5","key":"1383_CR3","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1080\/003655902320783845","volume":"36","author":"H Hedelin","year":"2002","unstructured":"Hedelin H, Holm\u00e4ng S, Wiman L (2002) The cost of bladder tumour treatment and follow-up. Scand J Urol Nephrol 36(5):344\u2013347","journal-title":"Scand J Urol Nephrol"},{"issue":"3","key":"1383_CR4","first-page":"111","volume":"79","author":"M Racioppi","year":"2007","unstructured":"Racioppi M, Volpe A, Falabella R et al (2007) The cost of treatment and follow-up of bladder cancer in Italy. Arch Ital Urol Androl 79(3):111\u2013117","journal-title":"Arch Ital Urol Androl"},{"issue":"12","key":"1383_CR5","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1097\/00000478-199812000-00001","volume":"22","author":"JI Epstein","year":"1998","unstructured":"Epstein JI, Amin MB, Reuter VR, Mostofi FK (1998) The World Health Organization\/International Society of Urological Pathology consensus classification of urothelial (transitional cell) neoplasms of the urinary bladder. Bladder Consensus Conference Committee. Am J Surg Pathol 22(12):1435\u20131448","journal-title":"Am J Surg Pathol"},{"issue":"7","key":"1383_CR6","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1002\/(SICI)1097-0142(20000401)88:7<1663::AID-CNCR21>3.0.CO;2-8","volume":"88","author":"L Cheng","year":"2000","unstructured":"Cheng L, Neumann RM, Nehra A, Spotts BE, Weaver AL, Bostwick DG (2000) Cancer heterogeneity and its biologic implications in the grading of urothelial carcinoma. Cancer 88(7):1663","journal-title":"Cancer"},{"issue":"4","key":"1383_CR7","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1080\/003655901750425837","volume":"35","author":"A Billis","year":"2001","unstructured":"Billis A, Carvalho RB, Mattos AC et al (2001) Tumor grade heterogeneity in urothelial bladder carcinoma\u2014proposal of a system using combined numbers. Scand J Urol Nephrol 35(4):275\u2013279","journal-title":"Scand J Urol Nephrol"},{"issue":"5","key":"1383_CR8","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1016\/j.eururo.2009.12.024","volume":"57","author":"RJ Sylvester","year":"2010","unstructured":"Sylvester RJ, Brausi MA, Kirkels WJ et al (2010) Long-term efficacy results of EORTC genito-urinary group randomized phase 3 study 30911 comparing intravesical instillations of epirubicin, bacillus Calmette-Gu\u00e9rin, and bacillus Calmette-Gu\u00e9rin plus isoniazid in patients with intermediate- and high-risk stage Ta T1 urothelial carcinoma of the bladder. Eur Urol 57(5):766\u2013773","journal-title":"Eur Urol"},{"issue":"2","key":"1383_CR9","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.eururo.2009.04.038","volume":"56","author":"PU Malmstr\u00f6m","year":"2009","unstructured":"Malmstr\u00f6m PU, Sylvester RJ, Crawford DE et al (2009) An individual patient data meta-analysis of the long-term outcome of randomised studies comparing intravesical mitomycin C versus bacillus Calmette-Gu\u00e9rin for non-muscle-invasive bladder cancer. Eur Urol 56(2):247\u2013256","journal-title":"Eur Urol"},{"issue":"6","key":"1383_CR10","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1016\/j.urology.2005.12.014","volume":"67","author":"RF Han","year":"2006","unstructured":"Han RF, Pan JG (2006) Can intravesical bacillus Calmette-Gu\u00e9rin reduce recurrence in patients with superficial bladder cancer? A meta-analysis of randomized trials. Urology 67(6):1216\u20131223","journal-title":"Urology"},{"issue":"3","key":"1383_CR11","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1046\/j.1464-410x.2001.02306.x","volume":"88","author":"MD Shelley","year":"2001","unstructured":"Shelley MD, Kynaston H, Court J et al (2001) A systematic review of intravesical bacillus Calmette-Gu\u00e9rin plus transurethral resection vs transurethral resection alone in Ta and T1 bladder cancer. BJU Int 88(3):209\u2013216","journal-title":"BJU Int"},{"issue":"6","key":"1383_CR12","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1016\/S0022-5347(05)67523-4","volume":"163","author":"M Brake","year":"2000","unstructured":"Brake M, Loertzer H, Horsch R, Keller H (2000) Recurrence and progression of stage T1, grade 3 transitional cell carcinoma of the bladder following intravesical immunotherapy with bacillus Calmette-Guerin. J Urol 163(6):1697\u20131701","journal-title":"J Urol"},{"issue":"3","key":"1383_CR13","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1111\/j.1464-410X.2012.11754.x","volume":"112","author":"NM Gandhi","year":"2013","unstructured":"Gandhi NM, Morales A, Lamm DL (2013) Bacillus Calmette-Gu\u00e9rin immunotherapy for genitourinary cancer. BJU Int 112(3):288\u2013297","journal-title":"BJU Int"},{"issue":"1","key":"1383_CR14","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.eururo.2013.07.021","volume":"65","author":"M Brausi","year":"2014","unstructured":"Brausi M, Oddens J, Sylvester R et al (2014) Side Effects of bacillus Calmette-Gu\u00e9rin (BCG) in the treatment of intermediate- and high-risk Ta, T1 papillary carcinoma of the bladder: results of the EORTC genito-urinary cancers group randomised phase 3 study comparing one-third dose with full dose and 1\u00a0year with 3\u00a0years of maintenance BCG. Eur Urol 65(1):69\u201376","journal-title":"Eur Urol"},{"issue":"5","key":"1383_CR15","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1111\/j.1445-2197.1998.tb04768.x","volume":"68","author":"DL Paterson","year":"1998","unstructured":"Paterson DL, Patel A (1998) Bacillus Calmette-Guerin (BCG) immunotherapy for bladder cancer: review of complications and their treatment. Aust NZ J Surg 68(5):340\u2013344","journal-title":"Aust NZ J Surg"},{"issue":"3","key":"1383_CR16","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1159\/000472760","volume":"13","author":"F Pagano","year":"1987","unstructured":"Pagano F, Garbeglio A, Milani C, Bassi P, Pegoraro V (1987) Prognosis of bladder cancer. I. Risk factors in superficial transitional cell carcinoma. Eur Urol 13(3):145\u2013149","journal-title":"Eur Urol"},{"issue":"3","key":"1383_CR17","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/j.eururo.2005.12.031","volume":"49","author":"RJ Sylvester","year":"2006","unstructured":"Sylvester RJ, Van der meijden AP, Oosterlinck W et al (2006) Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol 49(3):466\u2013475","journal-title":"Eur Urol"},{"issue":"4","key":"1383_CR18","doi-asserted-by":"crossref","first-page":"249","DOI":"10.3109\/01913123.2013.786772","volume":"37","author":"F Ajili","year":"2013","unstructured":"Ajili F, Darouiche A, Chebil M, Boubaker S (2013) The efficiency of the EORTC scoring system for the prediction of recurrence and progression of non-muscle-invasive bladder cancer treated by bacillus Calmette-Guerin immunotherapy. Ultrastruct Pathol 37(4):249\u2013253","journal-title":"Ultrastruct Pathol"},{"issue":"6","key":"1383_CR19","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1016\/S0022-5347(17)51695-X","volume":"130","author":"NM Heney","year":"1983","unstructured":"Heney NM, Ahmed S, Flanagan MJ et al (1983) Superficial bladder cancer: progression and recurrence. J Urol 130(6):1083\u20131086","journal-title":"J Urol"},{"issue":"2","key":"1383_CR20","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1023\/B:UROL.0000020305.70637.c6","volume":"35","author":"S Kr\u00fcger","year":"2003","unstructured":"Kr\u00fcger S, Thorns C, B\u00f6hle A, Feller AC (2003) Prognostic significance of a grading system considering tumor heterogeneity in muscle-invasive urothelial carcinoma of the urinary bladder. Int Urol Nephrol 35(2):169\u2013173","journal-title":"Int Urol Nephrol"},{"key":"1383_CR21","author":"ON Gofrit","year":"2013","unstructured":"Gofrit ON, Pizov G, Shapiro A, Duvdevani M, Yutkin V, Landau EH, Zorn KC, Hidas G, Pode D (2013) Mixed high and low grade bladder tumors\u2014are they clinically high or low grade tumors? J Urol. doi: 10.1016\/j.juro.2013.11.056","journal-title":"J Urol"},{"key":"1383_CR22","first-page":"3","volume":"310","author":"A Morales","year":"1989","unstructured":"Morales A (1989) BCG in the treatment of bladder cancer: state of the art. Prog Clin Biol Res 310:3\u201310","journal-title":"Prog Clin Biol Res"},{"issue":"3","key":"1383_CR23","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1016\/j.eururo.2012.10.039","volume":"63","author":"J Oddens","year":"2013","unstructured":"Oddens J, Brausi M, Sylvester R et al (2013) Final results of an EORTC-GU cancers group randomized study of maintenance bacillus Calmette-Gu\u00e9rin in intermediate- and high-risk Ta, T1 papillary carcinoma of the urinary bladder: one-third dose versus full dose and 1\u00a0year versus 3\u00a0years of maintenance. Eur Urol 63(3):462\u2013472","journal-title":"Eur Urol"}],"container-title":["World Journal of Urology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00345-014-1383-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00345-014-1383-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00345-014-1383-5","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,8,14]],"date-time":"2019-08-14T01:49:56Z","timestamp":1565747396000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00345-014-1383-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,8,23]]},"references-count":23,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2015,6]]}},"alternative-id":["1383"],"URL":"https:\/\/doi.org\/10.1007\/s00345-014-1383-5","relation":{},"ISSN":["0724-4983","1433-8726"],"issn-type":[{"value":"0724-4983","type":"print"},{"value":"1433-8726","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,8,23]]}}}